“Identification of significant predictors [of upstaging] has improved our pre-op counseling," says Neeraja Tillu, MD. A long-term, multicenter analysis of patients undergoing robot-assisted radical ...

Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).

Panelists discuss how regulatory approval of the radium-223 and enzalutamide combination would likely lead to significant guideline updates, particularly in treatment sequencing recommendations for ...

This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis. Yesterday, March 11, 2025, the US House of ...

“We might need to do a better job in general about education of the importance of follow-up,” says Christina B. Ching, MD. In a recent interview, Christina B. Ching, MD, of Nationwide Children’s ...

Piflufolastat F18 yields high detection rate even at low PSA levels for prostate cancer ...

"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD. Schuckman is an associate professor of urology/urologic oncology at the Keck School of ...

Panelists discuss how adapting the PEACE-3 protocol to real-world US patient populations requires careful consideration of broader patient demographics, comorbidities, and prior treatment histories ...

Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 ...

For the study, Morgans and her coauthors evaluated data for 284 patients. Of the cohort, 37% had known PSADT and 63% had unknown PSADT. More patients with known PSADT had characteristics of more ...

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

"At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months," says Jacob A. Moyer, BS. Moyer: Since nadofaragene firadenovec was approved in ...